|
| David Maher |
| |
Dr. Maher
has over 12 years of experience in the procurement, enforcement, and
licensing of intellectual property. His practice focuses on patent
prosecution, opinion work, and licensing, principally for the
biotechnological, chemical, and medical device industries. He has
considerable experience in European patent opposition practice, reissue
and reexamination proceedings, and portfolio analysis and diligence
reviews in conjunction with investments, licensing, and mergers and
acquisitions. David’s practice also benefits from substantial
experience in dispute resolution regarding patent infringement,
licensing, inventorship disputes and trade secret theft. |
|
 |
| |
David
has represented a variety of entities, including major corporations,
universities, start-ups and spin-offs, and individual inventors. As a
result of his time in industry, David is acutely aware of the issues
facing in-house counsel and can assist in meeting corporate goals.
David’s current and former clients include: Abbott Laboratories, Amgen, California Institute of Technology, Chiron, Eli Lilly, Genentech, Monsanto, The Regents of the University of California, Roche Molecular Systems, Sloan-Kettering Institute for Cancer Research, SRI International, and SUGEN.
|
| |
A
number of clients David has represented have been successfully
acquired, including GeoMed (acquired by Titan Pharmaceuticals), MetaXen
(acquired by Exelixis Pharmaceuticals), SUGEN (acquired by Pharmacia
Corporation for $750 million), and Quantum Dots (acquired by
Invitrogen). Patent portfolios he has developed have been described as
“very well protected” and “airtight” by his clients’ management after
diligence review by third parties. |
| |
David
has worked with technologies including molecular and cellular biology,
hybridization assays, solid phase and solution array detection methods
and devices, DNA amplification and sequencing, fluorescent imaging and
detection, fluorescence energy transfer, semiconductor nanocrystals,
dye chemistry, cytometry, kinases and kinase inhibitors, cytology and
histology, immunology, antibodies, medical diagnostics and treatment
methods, transgenic plants, oncology, virology, microbiology,
enzymology, pharmaceutical chemistry, formulations, drug delivery,
chemical synthesis, organic chemistry, inorganic chemistry,
organometallics, polymer chemistry, siloxanes, optoelectronic materials
and devices, and pollution control. |
| |
David
received his bachelor’s degree in chemistry from the University of
Notre Dame, where he was named a Notre Dame Scholar. He received his
Ph.D. in the Biochemistry Division of the Chemistry Department at the
University of California, San Diego, where he studied the
structure-function relationship of oncogenes, growth factors and
receptors, gaining skills in molecular and cellular biology and
biochemistry. At the University of Washington Medical Center, he served
as a Senior Fellow in the Vascular Biology Program, where he studied
tyrosine phosphatase expression and function in vascular smooth muscle
cells. He earned his J.D. from Santa Clara University, where he was
named an Emery School of Law Scholar. |
| |
Dr.
Maher is admitted to practice in California and before the U.S. Patent
and Trademark Office. He is a member of the American Intellectual
Property Law Association, the Licensing Executives Society, the San
Diego Intellectual Property Law Association, the American Chemical
Society, the Alpha Chi Sigma chemistry fraternity and the Phi Kappa Phi
and Alpha Epsilon Delta Honor Societies. In addition to the practice of
law, he enjoys astronomy, wine tasting, traveling, skiing, struggling
with golf, spending time with his family and coaching Little League. |
|
David can be reached by e-mail at david@techlawllp.com, by telephone at 858.228.7829, and by facsimile at 619.923.0888. |
|
|
